"T. Rowe Price Health Sciences capably wields its double-edged sword.
In contrast to his health-care-fund rivals, who mainly favor larger names, manager Kris Jenner has long gravitated to smaller fry. With broad product portfolios and already-giant revenue bases, one successful drug often barely moves big firms' bottom lines. For smaller names, the opposite is the case. One hit drug has a major impact. And they frequently address smaller markets and diseases the major players ignore. The companies can charge steep price tags because there aren't many or, in some cases, any alternative treatments, leading to fat profit margins.
Top holding Alexion Pharmaceuticals ALXN fits this profile. The company has just one marketable drug, recently approved Solaris, which treats a rare genetic blood disease. The drug's early success has pushed Alexion into the black, leading to handsome stock gains in 2010 and 2011. Jenner is apt to hang onto winners so long as their prospects remain strong, as is the case here. He expects revenues to double to $1 billion in three years.
Jenner's smaller-cap tilt has drawbacks. Because investors tend to favor the stabler behemoths in tough markets, the fund is especially vulnerable in downturns. And with at most a handful of marketable treatments, smaller firms also face more business risk. An adverse ruling from the FDA can send their share prices reeling.
Jenner hasn't been able to sidestep the risks of a down market. The fund landed in its group's bottom quartile in 2008, for example, sliding 28%. But Jenner has been adept in identifying health firms with big opportunities. That's allowed the fund to rebound nicely from downturns and to thrive in up markets. In the past decade, the fund's annualized gain of 7.8% places near the top of the health-care heap. Skilled management makes this fund a top-rate health-care investment."
(you can get
14 day free Morningstar Premium membership trial here:
http://members.morningstar.com/mk/t...referid=a3009&vurl=http://www.morningstar.com)